- Home
- BROG vs MCRB Comparison
BROG vs MCRB Comparison
Compare BROG & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- MCRB
- Stock Information
- Founded
- BROG 2019
- MCRB 2010
- Country
- BROG United Arab Emirates
- MCRB United States
- Employees
- BROG N/A
- MCRB N/A
- Industry
- BROG Integrated oil Companies
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- MCRB Health Care
- Exchange
- BROG Nasdaq
- MCRB Nasdaq
- Market Cap
- BROG 137.5M
- MCRB 131.0M
- IPO Year
- BROG N/A
- MCRB 2015
- Fundamental
- Price
- BROG $1.29
- MCRB $0.73
- Analyst Decision
- BROG
- MCRB Buy
- Analyst Count
- BROG 0
- MCRB 4
- Target Price
- BROG N/A
- MCRB $5.63
- AVG Volume (30 Days)
- BROG 56.3K
- MCRB 2.0M
- Earning Date
- BROG 02-15-2025
- MCRB 03-04-2025
- Dividend Yield
- BROG N/A
- MCRB N/A
- EPS Growth
- BROG N/A
- MCRB N/A
- EPS
- BROG N/A
- MCRB N/A
- Revenue
- BROG $73,020,415.00
- MCRB $126,325,000.00
- Revenue This Year
- BROG N/A
- MCRB N/A
- Revenue Next Year
- BROG N/A
- MCRB N/A
- P/E Ratio
- BROG N/A
- MCRB N/A
- Revenue Growth
- BROG N/A
- MCRB 12856.41
- 52 Week Low
- BROG $0.80
- MCRB $0.54
- 52 Week High
- BROG $6.66
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- BROG 46.04
- MCRB 37.88
- Support Level
- BROG $1.21
- MCRB $0.71
- Resistance Level
- BROG $1.46
- MCRB $0.91
- Average True Range (ATR)
- BROG 0.16
- MCRB 0.06
- MACD
- BROG -0.01
- MCRB -0.02
- Stochastic Oscillator
- BROG 35.42
- MCRB 8.37
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.